|
BEAUFOUR IPSEN SIGNS RESEARCH AGREEMENT WITH CAMBRIDGE UNIVERSITY.(Brief Article)
From:
European Report
| Date:
March 27, 2002
| COPYRIGHT 2002 Europe Information Service. This material is published under license from the publisher through the Gale Group, Farmington Hills, Michigan. All inquiries regarding rights should be directed to the Gale Group.Copyright information
|
The French pharmaceuticals group Beaufour Ipsen has signed a research and development agreement on the treatment of inflammatory diseases with Cambridge University. The agreement covers the development and marketing of chimiokine inhibitors developed by Docteur David Grainger of Cambridge University. Chimiokines are small proteins that regulate the immune system. Under the terms of the agreement between the two partners, Beaufour Ipsen will subsidise Dr Grainger's research ...
Related newspaper, magazine, and trade journal articles from HighBeam Research
(Including press releases, facts, information, and biographies)
For more facts and information,
see all results